Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Apr 8;22(5):275. doi: 10.1038/s41577-022-00722-3

Are variant-specific vaccines warranted?

Alexandra Flemming 1,
PMCID: PMC8990488  PMID: 35396462

The efficacy of current COVID-19 vaccines wanes over time, and viral variants, particularly Omicron, have lost many of the binding sites for neutralizing antibodies — leading to large numbers of breakthrough infections in vaccinated individuals. Vaccine boosters can restore protection (at least for a few months), and variant-specific boosters are currently being trialled. In a mouse model of COVID-19, Ying et al. demonstrate that boosting with an Omicron-specific version of mRNA-1273, as compared to the ‘original’ mRNA-1273, leads to enhanced protection against Omicron. However, full vaccination with the Omicron-adapted vaccine provided poor cross-protection against the ancestral virus. Meanwhile, Gagne et al. compared mRNA-1273 and Omicron-matched booster shots in macaques that had been vaccinated with mRNA-1273 months earlier. Following challenge with Omicron, both boosters induced 70–80% cross-protective B cells and provided complete protection in the lungs as well as comparable, limited protection in the upper airways. Given the uncertainty around potential new variants, broad protection may be preferable to variant-specific protection.

References

Original articles

  1. Gagne M, et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing antibodies and protection against Omicron. Cell. 2022 doi: 10.1016/j.cell.2022.03.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ying B, et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell. 2022 doi: 10.1016/j.cell.2022.03.037. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nature Reviews. Immunology are provided here courtesy of Nature Publishing Group

RESOURCES